CClinicalTrials.gg
CompletedNCT01686685ASD-CXCR4Updated Apr 12, 2018

Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months

An observational study in Autism Spectrum Disorder and Complication of Prematurity, sponsored by Hadassah Medical Organization. Completed at 1 site in Israel. Open to participants aged 1 Hour to 1 Day, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-12.

Sponsored by Hadassah Medical Organization · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
1 Hour to 1 Day
Sex
All
01

Study summary

Preterm children are at increased risk for autism spectrum disorders, with an estimated rate of 10%. In the US, about 1 in 8 pregnancies ends with a premature birth. Therefore, individuals with ASD who were born prematurely form a substantial body of children diagnosed with ASD.

Premature birth confers an insult to the newborn at a neurologically vulnerable stage. Prematurity associated changes in oxygen tension can be detrimental to developing organs, the brain being one of the most rapidly developing organs in the second half of the pregnancy. Changes in oxygen tension mediate activation of proteins that change the course of cell development.

In this study, we plan to measure changes in the expression of 3 proteins that may be affected by changes in oxygen level at birth. We will study the interaction between the proteins' levels in the first few days after premature birth with a diagnosis of ASD at 2 years of age. The proteins are:

  1. VEGF (Vascular Endothelial Growth Factor), a protein that takes part in creating new blood vessels during embryonic development.
  2. Hypoxia-inducible factor -1(HIF-1), a key protein that coordinates expression of different genes, many with developmentally critical functions.
  3. CXCR4, a cell surface protein that is activated by SDF-1. SDF- 1 is a molecule that regulates migration of cells to their target destination during embryonic life. CXCR4 is expressed in areas of the brain and on cells that are known to be associated with ASD.

We hypothesis that changes in oxygen tension in premature babies initiates a cascade of events that lead to changes in cell mobility via abnormal CXCR4 expression. This change leads to abnormal neurodevelopment.

The investigators' primary aim is to find if there is a correlation between postnatal levels of expression of HIF-1, CXCR4 and VEGF and a diagnosis of autism at age 24 months. The investigators' secondary aim is to find if there is a correlation between postnatal levels of expression of HIF-1, CXCR4 and VEGF and a language or neurocognitive delay.

Methods:

  1. Premature babies will be recruited in the first day post delivery.
  2. Blood samples will be collected at 3 time points during their hospitalization, and the expression of HIF-1, CXCR4 and VEGF will be determined.
  3. Infants will undergo a complete developmental evaluation at 18-24 months of age .
  4. Postnatal levels of HIF, CXCR4 and VEGF will be plotted against the results of the developmental evaluation.
02

Conditions studied

  • Autism Spectrum Disorder
  • Complication of Prematurity

Keywords

  • ASD
  • autism
  • prematurity
  • oxygen-dependant gene activation
  • CXCR4
  • Language delay
  • Cognitive delay
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's planned enrollment of 400 is above the median of 112 across 777 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Hadassah Medical Organization is the lead sponsor of 659 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Hour to 1 Day
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

neonatal intensive care units newborn ward

Inclusion criteria

  • Parents gave informed consent approved by the Institutional Review Board
  • Gestational week 28-34 as determined by an ultrasound during the first trimester
  • Singleton or twin pregnancy

Exclusion criteria

Exclusion Criteria:

  • Major anatomical abnormalities as detected on prenatal US
  • Genetic syndrome as detected by prenatal US, MRI or chorioamniocentesis
  • Obvious anatomical abnormalities or dysmorphic features detected on physical examination immediately following birth
  • Triplet pregnancy
  • Mother known or suspected to consume alcohol or illegal drugs during pregnancy
  • Mother took medications during pregnancy that are known to have adverse affects on development (e.g. anti-epileptics)
  • Family history of genetic syndrome related to developmental delays, that was not ruled out during current pregnancy (e.g. sibling with Tuberous Sclerosis or fragile X)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Diagnosis of ASD at 24 months corrected age

    Participants will be screened at 18 and 24 months for autism using the MCHAT questionnaire all positive screens will be referred for a complete developmental evaluation by child psychologist and developmental pediatrician: History, assessment (ADOS) and clinical judgement based on DSM criteria

    Time frame: 30 months

Secondary outcomes

  1. Language or cognitive delay at 24 months corrected age

    Participants will be screened by questionnaires at 18 and 24 months. all positive screens will be referred for a full developmental evaluation using the Mullen Scales of Early learning

    Time frame: 30 months

07

Study locations

1 site
  • Hadassah Medical Center
    Jerusalem, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01686685
Lead sponsor
Hadassah Medical Organization
Responsible party
Sponsor
First posted
Sep 18, 2012
Start date
Sep 2013
Primary completion
Apr 2018
Completion
Apr 1, 2018
Last update
Apr 12, 2018

Study contacts

Michal Begin, MD
study director · Hadassah HMO

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion